


Surface hygiene program moves to prototype development after further success

OBJ Limited (ASX:OBJ) has committed to the design and development of surface hygiene device prototypes after further successful studies into improved bacterial kill rate were completed by the University of Western Australia (UWA). The prototypes will be integral to partnering discussions for the technology which continue their recent advancement.

The recent round of technology developments saw OBJ commission UWA to conduct replicate studies into the direct effect of OBJ's micro-array in the treatment of *Streptococcus aureus*, or Golden Staph, a major source of infection in medical facilities with potentially life-threatening consequences.



The study by UWA explored the efficacy of benzalkonium chloride (BKC) with and without the enhanced penetration capabilities of OBJ's micro-array technology. The new study reconfirmed the effectiveness of OBJ's technology following a test undertaken in

2015. Further to this, the new results show a similar bacterial kill rate for the same disinfectant (BKC) as was witnessed in 2015.

With exposure to OBJ's micro-array the effectiveness of BKC was found to increase by two-to-three times when compared to use of the same disinfectant alone, over all time periods for the tests performed in bacterial suspensions.

This further confirmation of the ability of OBJ's micro-array technology to give a pronounced improvement in bacterial kill rate is thought to be effected by driving disinfectant agents such as BKC deeper into the micro-fissures and scratches found in surfaces such as stainless steel and aluminium benchtops and various flooring treatments. The testing program will continue at UWA across a number of influencing factors, measuring the effectiveness on different surfaces commonly found in domestic and commercial applications.

This reconfirmation has encouraged OBJ management to now commit with prototype development of a number of potential commercial devices for use in the homecare, floor cleaning, hospitality, hospital and industrial hygiene market sectors. Market research to date has identified several exciting applications for the use of micro-array technology including hand held surface treatments and floor cleaning devices.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville

Western Australia 6007

Tel: +61 8 9443 3011

Fax: +61 8 9443 9960

www.obj.com.au

ABN: 72 056 482 636

Development of the first prototypes will greatly facilitate discussions currently taking place with a number of potential partner companies who have shown a high level of interest in the technology. This will also enable OBJ together with partnering companies demonstrate the consumer response to the use of such devices.



OBJ is working with award-winning Sydney based industrial design firm Design and Industry in developing the prototypes. These will initially focus on devices for the homecare and hospitality sectors ahead of further partnering discussions with various fast moving consumer goods (FMCG) companies.

Design and Industry is currently engaged by OBJ to create a number of innovative products as part of the product development agreement (PDA) with Procter & Gamble, including several products that were the subject of recently reported licencing term sheets.

The surface cleaning market in the US alone generates an estimated \$4.7 billion in annual sales.

OBJ Managing Director Jeff Edwards said: “These encouraging new developments further validate the commercial potential for OBJ’s surface hygiene program. Various potential FMCG partners have shown growing interest in recent times and we are now accelerating the surface hygiene program with the commitment of such additional resources.”



About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward Looking Statements

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.



OBJ RELEASE
14 June 2016

For more information:

OBJ Limited:

Mr Glyn Denison – Director

www.obj.com.au

284 Oxford Street

Leederville

Western Australia 6007

Phone: +61 8 9443 3011

Fax: +61 8 9443 9960

Media/Investor relations:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420

Registered Office:

284 Oxford Street

Leederville

Western Australia 6007

Tel: +61 8 9443 3011

Fax: +61 8 9443 9960

www.obj.com.au

ABN: 72 056 482 636